The Pig-a Gene Mutation Assay in Mice and Human Cells : A Review by Olsen, Ann-Karin et al.
MiniReview
The Pig-a Gene Mutation Assay in Mice and Human Cells:
A Review
Ann-Karin Olsen1,2, Stephen D. Dertinger3, Christopher T. Kr€uger4,†, Dag M. Eide2,5, Christine Instanes1,2, Gunnar Brunborg1,2,‡,
Andrea Hartwig4 and Anne Graupner1,2
1Department of Molecular Biology, The Norwegian Institute of Public Health, Oslo, Norway, 2Centre for Environmental Radioactivity (CERAD
CoE), Norway, 3Litron Laboratories, Rochester, NY, USA, 4Food Chemistry and Toxicology, Karlsruhe Institute of Technology (KIT), Karlsruhe,
Germany and 5Department of Toxicology and Risk, The Norwegian Institute of Public Health, Oslo, Norway
(Received 19 December 2016; Accepted 1 May 2017)
Abstract: This MiniReview describes the principle of mutation assays based on the endogenous Pig-a gene and summarizes
results for two species of toxicological interest, mice and human beings. The work summarized here largely avoids rat-based
studies, as are summarized elsewhere. The Pig-a gene mutation assay has emerged as a valuable tool for quantifying in vivo and
in vitro mutational events. The Pig-a locus is located at the X-chromosome, giving the advantage that one inactivated allele can
give rise to a mutated phenotype, detectable by multicolour flow cytometry. For in vivo studies, only minute blood volumes are
required, making it easily incorporated into ongoing studies or experiments with limited biological materials. Low blood volumes
also allow individuals to serve as their own controls, providing temporal information of the mutagenic process, and/or outcome
of intervention. These characteristics make it a promising exposure marker. To date, the Pig-a gene mutation assay has been
most commonly performed in rats, while reports regarding its usefulness in other species are accumulating. Besides its applicabil-
ity to in vivo studies, it holds promise for genotoxicity testing using cultured cells, as shown in recent studies. In addition to
safety assessment roles, it is becoming a valuable tool in basic research to identify mutagenic effects of different interventions or
to understand implications of various gene defects by investigating modified mouse models or cell systems. Human blood-based
assays are also being developed that may be able to identify genotoxic environmental exposures, treatment- and lifestyle-related
factors or endogenous host factors that contribute to mutagenesis.
Paroxysmal nocturnal haemoglobinuria (PNH) is a genetic dis-
order that affects 1–10 per million individuals and is caused
by somatic PIG-A gene mutations within a bone marrow stem
cell [1]. The PIG-A gene encodes a catalytic subunit of the N-
acetylglucosamine transferase complex involved in the synthe-
sis of glycosylphosphatidylinositol (GPI) cell surface anchors
[2]. Inactivating mutations inhibit the biosynthesis of GPI
anchors, causing a deficiency in GPI-anchored proteins on the
cell surface, for example CD59, CD55 and CD24. PNH usu-
ally affects erythrocytes, granulocytes and monocytes. In a
minority of cases, the lymphocyte lineage is also affected. As
a cell surface phenotype present on readily accessible
haematopoietic cells, flow cytometry-based techniques that
measure the frequency of CD59- and/or CD55-deficient red
blood cells have replaced the traditional HAM test (acid-
induced disruption of the fragile red blood cells of patients
with PNH) for PNH diagnosis [3,4]. Work directed at elucidat-
ing the aetiology of PNH and creating flow cytometry-based
diagnostic tests provided an important starting point for the
development of mutation assays that utilize the Pig-a/PIG-A
loci as reporters of gene mutation.
The earliest reports that suggested that PIG-A may repre-
sent a useful reporter of gene mutation were from the group
of Luzzatto [5] and later Chen [6]. These groups focused on
human cells, often transformed lymphocytes grown in cell
culture, or freshly isolated blood leucocyte population(s) [5–
9]. Several extended this work to rodent blood erythrocytes
and/or reticulocytes in order to provide regulatory safety
assessment laboratories with a practical and efficient platform
for evaluating chemical or physical agents’ potential to cause
gene mutation in vivo [10,11]. To date, this work has primar-
ily been accomplished in rats, as a key rodent model used in
regulatory toxicology studies [12,13]. However, the success-
ful application of phenotypic Pig-a-mutant scoring methods
in cell lines and mouse models is important given their
prominent role in both regulatory toxicology and basic
research. As much understanding has been accomplished and
described for rats, the purpose of this MiniReview was to
first introduce the Pig-a assay in detail followed by a
description of the current status for cell lines, mouse models
and human beings.
The scientific literature was searched in PubMed using key-
words such as Pig-a, PIG-A, mutation, paroxysmal nocturnal
haemoglobinuria, mouse, human beings, TK6 and followed by
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manual selection of relevant articles using a version of the
Pig-a/PIG-A assays as main inclusion criteria. The studies are
presented in tables 1 and 2 according to the publication year.
Principle of the Assay
Iida et al. [14] isolated the human PIG-A gene and found
that it contains six exons over its 17 kb length. As demon-
strated by Kawagoe et al. [15], there is a high degree of
interspecies conservation of the gene’s structure, function and
position on the X-chromosome. The gene product plays a
critical role in the first step in GPI anchor biosynthesis, and
the entire process is thought to require at least two dozen
genes. Mutation of any one of these genes could theoretically
result in GPI anchor deficiency. However, all other genes
involved in GPI anchor synthesis are autosomal. Mutations
on both alleles would have to occur to ablate expression of
GPI anchors, and this is expected to be an exceptionally rare
event, at least when all other GPI anchor-associated gene
alleles are both functional. Thus, the single-copy status of the
Pig-a/PIG-A gene is a critical feature that makes it useful as
a phenotypic reporter of gene mutation, because only one
mutational event is sufficient to completely ablate expression
of GPI anchors.
The evidence that GPI anchor deficiency represents a valid
reporter of Pig-a/PIG-A mutation starts with investigations of
PNH. One key finding is that with only extremely rare excep-
tions PNH clones exhibit mutation at the PIG-A locus. For
instance, Nishimura et al. [16] analysed 146 patients with PNH
and reported the types of mutations that lead to GPI anchor
deficiency, all within the PIG-A locus. Single-base substitu-
tions and frame-shift events were the most highly represented
classes of mutations observed. They also found three examples
of large deletions (entire gene, 4 kb and 737 base pairs), as
well as a large insertion (88 base pairs). The mutations were
widely distributed in the coding regions and splice sites,
although Nafa et al. [17] found a somewhat higher frequency
of missense mutations in exon 2 relative to other exons. Taken
together, the PNH literature provides strong support for the
concept that the GPI anchor-deficient phenotype represents a
useful reporter of Pig-a mutations, and such assays would be
sensitive to several important classes of mutations.
The cell surface of haematopoietic cells is dramatically
affected by Pig-a/PIG-A mutations. For example, CD59,
CD55 and/or CD24 are highly expressed on haematopoietic
cells, and these expression levels are maintained throughout
cells’ lifespan. However, when bone marrow cells experience
an inactivating Pig-a/PIG-A mutation, after a sufficient period
of manifestation time, progeny cells show a complete absence
of these markers. The significant changes to specific cell sur-
face markers as a result of Pig-a/PIG-A mutations are readily
detected using fluorescent antibodies in conjunction with flow
cytometry. Furthermore, blood cells as well as lymphoblastoid
cells in culture are highly compatible with flow cytometric
analysis. These characteristics combine to make flow cytome-
try the method of choice for efficiently scoring Pig-a/PIG-A-
mutant cells (fig. 1).
Variations in the basic approach of scoring mutant cells
(mostly blood cells) via flow cytometry in conjunction with flu-
orescent antibody labelling have been described. For instance,
for some cell types, it is possible to use the fluorescent-labelled
aerolysin reagent (FLAER) instead of antibody(ies). Whereas
antibodies recognize wild-type cells via their recognition of
GPI-anchored protein(s), FLAER binds with high affinity to
GPI anchors themselves. When the frequency of spontaneous
mutant phenotype cells is very low, as in the case for rat and
mouse erythrocytes and reticulocytes, the use of immunomag-
netic separation technologies is convenient. In this approach,
the number of reticulocytes evaluated for the mutant phenotype
is enriched, thus decreasing the data acquisition time [18].
Alternatively, one may use immunomagnetic separation to
specifically deplete the wild-type cells in each sample. In this
scenario, flow cytometric analysis of immunomagnetically sep-
arated samples provides the means to efficiently evaluate orders
of magnitude more erythrocytes and reticulocytes for the
mutant phenotype than would otherwise be possible, leading to
lower scoring errors [19]. These immunomagnetic separation
techniques can be especially important when study designs
seek to keep treatment group sizes modest while at the same
time ensuring sufficient statistical power to detect modest
changes to spontaneous mutant cell frequencies. This experi-
mental refinement greatly adds to the sensitivity of the assay,
due to the enrichment of unstained mutants and thus analysis
of manyfold more potential mutant cells (fig. 2).
One important aspect of the assay is that the mutants scored
by antibody staining and flow cytometry are phenotypical
mutants. Verification of these phenotypic mutants as true Pig-
a/PIG-A mutants by DNA sequencing analyses is vital for
confirmation of mutation frequencies measured and to demon-
strate the true nature of the mutants. Such identification has
been demonstrated in bone marrow erythroids of mice [20]
and CD48-negative T cells of N-ethyl-N-nitrosourea (ENU)-
and 7,12-dimethylbenz[a]anthracene (DMBA)-treated rats
[21,22]. The latter was performed by flow cytometric sorting
of mutant cells and sequencing of the Pig-a gene of expanded
single cells [21,22]. The induced mutation spectra obtained
were consistent with expected spectra obtained in other
endogenously expressed genes, verifying the validity of the
mutation frequencies measured. In human cells, point muta-
tions as well as deletions in PIG-A have been identified in
TK6 cell lines [23,24]. Recently, heterogeneous pools of Pig-
a-mutant T cells derived from DMBA-exposed rats were
efficiently sequenced by an elegant novel technique named
mutation analysis with random DNA identifiers (MARDI),
requiring no clone-by-clone analyses [25]. The MARDI tech-
nique facilitates verification of Pig-a mutants in a more feasi-
ble manner than previous strategies. Using the MARDI
technique, nearly all previously found Pig-a mutations were
identified, and new mutations were detected.
Pig-a in Mice
Searching the scientific literature, we identified 21 studies in
mice (summarized in table 1). In 2008, the first study to
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demonstrate cross-species potential from rats to mice was pub-
lished [26]. In this study, CD-1 mice were exposed to the car-
cinogen DMBA and the alkylating agent ENU and showed
clear induction of Pig-a mutations in both reticulocytes (RET,
immature red blood cells) and red blood cells (RBCs) [26].
The conclusion was that the Pig-a assay could be effectively
applied to in vivo-exposed mice. The temporal dynamics of
mutation induction and potential selection of mutant cells were
important issues to comprehend also in mice, to conduct
appropriate dosing regimens and to determine the optimal tim-
ing of measuring mutation frequencies. Hence, mutation fre-
quencies were determined weekly for 5 weeks after exposure
to ENU, showing that mutant RETs preceded mutant RBCs,
as expected, and that the effect persisted for the 5 weeks in
both RBCs and RETs. This study was followed by two studies
in C57BL/6 [27] and CD-1 mice [20]. In both studies, mice
were exposed to ENU and showed significant induction of
Pig-a mutations in RETs and RBCs (i.e. increased RET mean
Mf at day 2 of 700 9 106 compared to vehicle control mean
Mf ranging from 0.2 to 2.2 9 106). These initial studies con-
tributed with information regarding important descriptors of
the assay which includes understanding the kinetics of the
mutagenic process: mutation induction, maximum response
time and potential persistence. For information regarding mag-
nitude of effects, see table 1. Pig-a mutants appear slightly
faster in mice [26,27] than in rats [28]. After exposure to
ENU in mice, the maximum response appeared in week 2
after dosing in RETs and in week 4 in RBCs [26,27]. In rats,
the maximum response in RBCs started 6 weeks after the end
of exposure to ENU [28,29]. Moreover, in mice, the RBC-
mutant frequencies decrease slowly after reaching maximum,
whereas they persist in rats for at least 6 months [27,28]. In
both mice and rats, ENU-induced Pig-a mutants clearly accu-
mulate, as shown by two studies comparing single doses with
split doses [27,28]. In rats, the accumulation was nearly addi-
tive (57.3 9 106 in the 8.9 mg/kg single exposure group and
176.8 9 106 in the split group given four weekly doses of
8.9 mg/kg) [28], whereas in mice, the relative mutant numbers
were somewhat lower than in the rat in the split dosing regime
compared with single dosing (a single dose of 32 mg/kg com-
pared to four weekly doses of 8 mg/kg gave rise to mean Mfs
of 180 versus 105 9 106, respectively) [27]. Other studies
have confirmed the mutagenicity of ethylating agents such as
ENU [20,30,31] and ethyl methanesulphonate (EMS) [32].
Several polycyclic aromatic hydrocarbons (PAHs) have
been tested using the Pig-a assay in mice [26,30,31,33,34].
Both DMBA [26] and the benzo[a]pyrene (BaP) [30,31,33,34]
showed clear induction of Pig-a mutants. Mutagenic effect of
BaP was evident after different exposure scenarios in several
mouse strains. This includes 28-day dosing by oral gavage in
the MutaTM mouse model [33], a single oral dose in Gpt delta
mice [30], intraperitoneal injection for 3 days in C57BL/6
wild-type and DNA repair-deficient (Ogg1/) mice [34] and
recently also after 3 days of exposure by oral gavage in CD-1
mice [31]. This demonstrates that for the prototypical muta-
genic PAHs DMBA and BaP, the mouse Pig-a gene mutation
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Table 2.
Overview of PIG-A studies in human cells.
Study
classification1 Cell type(s) Experimental details
Main outcome, mutation rates and
mutation frequencies (Mf) References
A Eight mutator colon cancer lines
(defective in mismatch repair) and
four non-mutator cancer lines
Enrichment of mutants using the
GPI anchor-reactive bacterial toxin
aerolysin
All mutator colon cell lines have
higher Mf (42–74 9 106) than
control cell lines. Verification of
mutant cells by DNA sequencing
[6]
B, C B-lymphoblastoid cell lines from
normal donors, Fanconi anaemia
(FA) and ataxia telangiectasia (AT)
patients
Existing mutants were omitted by
cell sorting of anchor-positive cells
The mutation rate in normal donors
were 10.6 9 107 per cell division
(range 2.4–29.6) and was clearly
elevated in cell lines from the
cancer-prone FA (mean
411 9 107) and AT patients
(mean 40.1 9 107)
[50]
A, B B-lymphoblastoid cell lines (BLCL)
from normal donors, transformed
lymphoma (TL), Mantle cell
lymphoma (MCL), T-cell ALL
(TCA), marginal zone lymphoma
(MZL)
Depletion of existing mutants by
flow sorting of anchor-positive
cells
BLCL and MZL exhibit low
mutation rates with 11–17
mutations per 107 cell division
compared to the mutation rates of
TL, MCL and TCA ranging from
170 to 3286 mutations per 107 cell
division
[47]
B Red blood cells Blood from 97 normal individuals
and 10 individuals undergoing
chemotherapy
Mean Mf in RBCCD59 from normal
donors was 5.1  4.9, with 75%
showing <8. Two individuals,
however, showed very high Mf of
100 and 300. No clear correlation
with age and smoking status.
Patients undergoing chemotherapy
had generally weak responses, up
to threefold increases
[51]
D Lymphocytes isolated from full
blood. Exposure occurred in 1994;
blood collection occurred in 2009
35 Gulf War veterans exposed to
depleted uranium. Individuals were
divided into low-U (<0.10 lg U/g
creatinine) and high-U groups
(≥0.10 lg U/g creatinine)
PIG-A Mfs ranged from 2.9 to
113 9 106 (mean = 14.91
9 106). Group means
(18.13 9 106  4.85 for
low U and 9.45 9 106  0.81
for high U) were not significantly
different between the two exposure
groups, although a non-significant
reduction in the mean mutation
frequency in the high-exposure
group was apparent (numbers not
adjusted for age). Trend for a
positive association with age
[8]
A Myeloid cells CD34+ cells transduced with either
AML-ETO or MLL-AF9 fusion
genes and expanded with cytokines
The median mutation rate in AML-
ETO cells was 9.4 9 107 (range
3.6–23 9 107) per cell division.
Only few mutations were observed
in the MLL-AF9-transduced cells
[48]
B Peripheral blood granulocytes from
142 individuals.
Mutants identified as CD59/CD55/
CD24-negative cells
The median Mf was 4.9 with
significant interindividual
variability with Mf ranging
between <1 and 37.5
[9]
A,C Lymphoblastoid cell lines (LCL)
with mutations in the MUTYH
DNA repair protein from patients
with colorectal polyposis cancer
Mutants identified as CD59/CD55/
CD24-negative cells
The cell lines exhibited a fourfold
increased Mf (mean Mf of 87.6)
compared with LCLs from healthy
donors (mean Mf 21.7). The
mutant cells were also
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Table 2. (continued)
Study
classification1 Cell type(s) Experimental details
Main outcome, mutation rates and
mutation frequencies (Mf) References
C Lymphoblastoid cells lines (LCL)
expressing biallelic or monoallelic
variants of the MUTYH DNA
repair gene
Mutants identified as CD59/CD55/
CD24-negative cells.
LCLs homozygous for two MUTYH
mutations exhibited mutator
phenotypes with three- to sixfold
increases. Exposure of cells to the
oxidative stressor KBrO3 leads to
increased Mf
[53]
E TK6 cells EMS: 30 lM over night. Assayed at
days 1, 3, 6, 8 and 10
Selection of pro-aerolysin GPI
anchor-deficient isolates in the
TK6 cell line. Spontaneous and
EMS-induced mutants are
characterized by DNA sequencing.
Discover that the parent TK6 line
is hemizygous for PIG-L. EMS-
treated cells GPI-a Mf of
20 9 106 (background) to
470 9 106 (day 10). Few mutants
were verified as PIG-A mutants,
while many as PIG-L mutants
[23]
B Peripheral blood erythrocytes from
52 non-smoking, self-reported
healthy adults
Mutants were identified as CD59/
CD55-negative RBC and RET.
Immunomagnetic enrichment of
mutants. Technical replicated
included to achieve sufficient cell
numbers and for investigations of
assay variability
The mean frequency of Mf was 6.0
in RETs and 2.9 in RBCs,
consistent with a modest selective
pressure in circulation.
Intraindividual variability was low,
while interindividual variability
was relatively high (RET>30-fold).
The Mf increased with increasing
age. Cold whole blood can be held
for a week without changing the
Mf
[52]
E B-lymphoblastoid TK6 cells EMS: 200–800 lM (4 hr) and
100–200 lM (24 hr); UVC:
2–8 J/m2; 4-NQO: 50–200 nM;
Pyr: 1–10 mM; Cyhex: 1–10 mM.
Incubation for 4 hr or 24 hr
(EMS), assayed 10 days or
11 days after exposure,
respectively. Mutants were
identified as CD59/CD55
negative cells. Elimination of pre-
existing mutants was made using
antibody-coated cell dishes.
Generation of mutant suspension
was performed by pro-aerolysin
lysis of WT cells.
Dose-related increases in Mf after
exposure to EMS, UV-C and 4-
NQO (2- to 7.5-fold increases
compared to control). No increases
in Mf for the negative controls Pyr
and Cyhex. Mf increases reached a
plateau at day 10 which was
maintained at least until day 14
[54]
E B-lymphoblastoid TK6 cells and
TK6-related p53-deficient
WI-L2-NS cells
EMS: 200–800 lM, 4-hr incubation;
UVC: 2–8 J/m2
Dose-related increases in Mf after
exposure to EMS or UVC in both
cell lines, lower response in WI-
L2-NS cells for both mutagens.
Identification of a heterozygous
deletion in one copy of the
autosomal PIG-L in TK6 cells that
may serve as a second target for
mutation detection by one hit
[24]
Mf 9 106, mutation frequency; GPI, glycosylphosphatidylinositol; LCL, lymphoblastoid cells lines; MUTYH, MutY DNA glycosylase; RBCs,
red blood cells; RETs, reticulocyte; EMS, ethyl methanesulphonate; UVC, ultraviolet radiation C; 4NQO, 4-nitroquinoline-1-oxide; Pyr, pyridine;
CyHex, cycloheximide.
1The studies are classified using letter codes. Studies in A: cancer cells; B cells from normal donors; C: cells with impaired DNA damage response
or DNA repair defects; D: human lymphocytes exposed to environmental stressors; E: the TK6 cell line.
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Mutagenic effects of ionizing radiation such as X-rays and
gamma irradiation have been studied [35–37] and provide
valuable information concerning timing of mutant induction
and elimination in mice, as well as responses after acute ver-
sus protracted/chronic exposure to mutagens. Moreover, in
contrast to many chemicals, ionizing radiation does not
depend on metabolic activation to exert its effects. For X-rays,
a version of the Pig-a assay using anti-CD24, anti-TER-119
and anti-CD71 to detect the Pig-a-mutant frequencies in RBCs
and RETs was used. Single and protracted exposures (single
dose of 0.5, 1 and 2 Gy or fractionated dose of 4 x 0.5 Gy
once a week) to X-ray (0.52 Gy/min) resulted in comparable
dose- and time-dependent increases in Pig-a-mutant frequen-
cies, which subsequently declined over time returning to back-
ground frequencies [35]. After single dosing, the maximum
response occurred at days 7–21, whereas after protracted dos-
ing the maximal response occurred at day 42. There were
marked interindividual differences, both in the magnitude of
the maximal response and in time until maximum response
was evident. This study was followed up by investigations of
the role of p53 for X-ray-induced Pig-a mutants, showing that
the persistence of mutated RBCs was slower in p53/ mice
than in wild-type mice and that Pig-a mutations increased with
increasing age of p53/ mice [36]. These studies used acute
high dose rates (0.52 Gy/min) of X-rays. A pertinent issue is
to understand the outcome of low dose rate exposures to
gamma irradiation, which is more relevant to the general pop-
ulation, either alone or in combination with other natural co-
stressors. We recently published a study on single and com-
bined effects of continuous chronic low dose rate gamma
exposure and selenium deprivation via diet in a mouse model
with deficient repair of oxidized DNA (8-oxoguanine DNA
glycosylase-deficient mice; Ogg1/) and control animals. The
main result of this study was that gamma radiation given in a
more environmentally relevant exposure manner (1.48 mGy/hr
for 45 days to a total dose of 1.5 Gy) is indeed genotoxic in
mice [37]. One of several methods used to determine geno-
toxic effects was the Pig-a gene mutation analyses. This assay
Fig. 1. Glycophosphatidylinositol (GPI)-dependent genotype-to-phenotype relationship. Inactivating mutations in the PIG-A gene cause the GPI-
deficient phenotype identified as PIG-A mutants by the lack of immunostaining of anchor proteins such as CD55 and CD59. This is due to the X-
chromosomal location of PIG-A, which requires inactivation of one allele only (adapted from Kr€uger et al., 2015).
Fig. 2. Bivariate plots showing nucleic acid dye versus anti-CD24-PE fluorescence profiles (mouse blood example). Note that only gated events
(i.e. erythrocytes) are shown. Key to quadrants: upper right = wild-type reticulocytes (WT Rets-1); lower right = wild-type mature erythrocytes
(mutant normochromatic erythrocytes; WT NCE-1); upper left = mutant phenotype reticulocytes (mutant Rets-1); lower left = mutant phenotype
mature erythrocytes (mutant normochromatic erythrocytes; mutant NCE-1). Plot A: instrument calibration standard (ICS); blood that was fully pro-
cessed was spiked with mutant-mimicking cells (i.e. erythrocytes that were not incubated with anti-CD24-PE). This ICS is used to set PMT volt-
ages and compensation settings. The ICS also provides enough cells in order to rationally and consistently setting the position of the vertical
demarcation line that discriminates mutant phenotype erythrocytes from wild-type erythrocytes. Plot B: blood from an N-ethyl-N-nitrosourea
(ENU)-treated mouse, pre-column analysis (i.e. before immunomagnetic separation); this blood sample was obtained from a mouse 15 days after
the last of three administrations of ENU. A brief analysis of the pre-column blood sample is used to determine the numbers of total reticulocytes
and total erythrocytes that are applied to the immunomagnetic separation procedure (i.e. these are the denominators for mutant cell frequency calcu-
lations). Plot C: blood from the same ENU-treated mouse, post-column analysis (i.e. after immunomagnetic separation); this sample was depleted
of wild-type erythrocytes via immunomagnetic separation. With a subsequent centrifugation step, mutant phenotype cells become highly concen-
trated. The number of mutant reticulocytes and mutant erythrocytes is directly determined from this sample.
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was assessed 2 weeks after the end of continuous irradiation.
In general, gamma irradiation caused a moderate but signifi-
cant increase in the frequency of mutant RBC and no signifi-
cant effect of the genotype or diet alone. The frequency of
mutant RET was not significantly affected by any factor (i.e.
irradiation, diet or genotype) alone, whereas radiation and diet
together had a statistically significant impact on the frequen-
cies of mutant RET and RBC, suggesting an interaction
between the two factors. Micronucleated blood cells were
clearly induced by the chronic continuous low dose rate of
gamma irradiation, irrespective of mouse genotype and diet.
This study demonstrated that prolonged low dose rate expo-
sures to ionizing radiation are barely detectable in the Pig-a
assay when measured 2 weeks after cessation of treatment,
with significant interindividual variation. In mice, the maxi-
mum response after protracted exposures seems to occur later
than after acute exposures [35], so in the study by Graupner
et al. [37], an additional measurement time-point at 4 weeks
after exposure cessation would have given valuable informa-
tion. Acute exposure to ionizing radiation, on the other hand,
clearly induces Pig-a mutants [35].
Other agents besides ionizing radiation inducing DNA dam-
age through the production of reactive oxygen species are rep-
resented by the carcinogen 4-nitroquinoline 1-oxide (4-NQO),
investigated in the Pig-a assay in mice [30]. Comparisons
were made between Pig-a- and Gtp delta-mutant frequencies
in transgenic Gtp delta mice. 4-NQO induced weak insignifi-
cant increases in bone marrow cells in both the Pig-a and Gtp
assays, whereas a significant increase in Gtp-mutant frequency
was observed in the liver, which is target tissue for 4-NQO.
These results are in line with recommendations from the Inter-
national Workshop on Genotoxicity Testing (IWGT) [13] that
blood-based Pig-a assays will tend to benefit from immuno-
magnetic separation strategies allowing scoring of more cells
than are otherwise practical, and taking care not to interpret
negative Pig-a results as evidence of no in vivo mutagenic
potential.
Genotoxicity of two kinds of nanoparticles has been charac-
terized using the Pig-a assay [38–41]. The first study investi-
gated the genotoxic properties of titanium dioxide anatase
nanoparticles (TiO2-NPs, intravenous (i.v.) injection) in mice
observing no significant elevation of Pig-a mutants or
micronucleated blood cells [38]. In the second study, silver
nanoparticles (AgNP) were injected into mice [39]. Both stud-
ies confirmed – using analytical methods – that the nanoparti-
cles reached the bone marrow, but no increases in mutant
RET or RBC nor micronucleated RETs were detected when
measured 1, 2, 4 or 6 weeks after injection. However, the
levels of DNA lesions, measured using the alkaline comet
assay, were elevated. The third study exposed Gpt delta trans-
genic mice to TiO2-NP by i.v. injections for up to 4 weeks
[40] to study genotoxicity using an array of genotoxic end-
points in blood including the Pig-a assay. All end-points were
negative, indicating that nanoparticles are not genotoxic in
blood cells as shown by the lack of induction of RET or RBC
Pig-a gene mutations or micronucleated RETs as well as other
genotoxic end-points.
Nutrient deficiencies such as vitamin or essential element
deficiencies may give rise to genotoxic effects in mice investi-
gated using the Pig-a assay [42,43]. Mice were deprived of the
antioxidant and essential element selenium through depletion
starting in the parental generation [42]. Genotoxicity was moni-
tored in offspring where DNA lesions were clearly induced in
lung and testicular cells using the alkaline comet assay. How-
ever, no increased level of DNA lesions was evident in blood
cells and Pig-a-mutant frequencies in RETs and RBCs remained
unchanged. This indicates that selenium deprivation is not geno-
toxic to bone marrow or blood cells and that testicular and lung
cells as more susceptible cells. Folate is a B vitamin and folate
deficiency leads to mutations and genome instability. Mice were
fed a diet that was deprived, adequate or supplemented with
folate [43]. The mutant RET and RBC frequencies were similar
in mice given the deprived and the adequate diets, whereas the
mutant RBC frequency in mice given the deprived diet was
higher than in mice given the supplemented diet. The mutant
RBC frequencies of the mice given the deprived diets varied
significantly. The authors suggest that the results indicate that
adequate folate protects against mutagenesis.
Other compounds that have been tested in mice using the
Pig-a assay include the antineoplastic hydrazine derivative
procarbazine showing a significant induction of both mutant
RETs and RBCs [44]. The chlorinated organic solvents 1,2-
dichloropropane and dichloromethane, suggested to be
involved in the induction of cholangiocarcinoma in workers,
were tested in two mouse strains giving negative results for
RBCCD24 cells [41]. In the liver, DNA damage as measured
in the alkaline comet assay as well as Gpt mutation frequen-
cies was increased.
Importantly, Labash et al. [31] compared the response in
Pig-a mutation frequencies after exposure of mice to known
mutagens [ENU, BaP and ethyl carbamate (EC)] as well as two
structurally related non-mutagens (pyrene and methyl carba-
mate). The results clearly demonstrate that the mutagens gave
statistically significant increases in mutant RET and RBC muta-
tion frequencies, whereas the two non-mutagens did not.
Acrylamide is a compound known to induce tumours in
rodents. However, there is still controversy regarding the
mode of action for the tumour induction. Recently, Hobbs and
coworkers published a study where they measured Pig-a muta-
tion frequencies in rats and mice exposed to acrylamide in
drinking water for 30 days [45]. The applied doses spanned
and exceeded the doses used for the determination of the car-
cinogenic effects. They assayed Pig-a mutations the day after
the last dosing, a timing that may not be the most suitable to
reveal effects, showing equivocal effects. Given humans’ low
but widespread exposure to acrylamide, further work with this
compound may be warranted.
Recently, a study concerning mutagenicity as a result of
diet-induced obesity was published [46]. These investigators
observed significantly higher and sustained mutant RBC fre-
quency but not RET frequency in diet-induced obese C57BL/
6J mice given a high-fat diet compared to lean mice given a
normal-fat diet. They attributed the significant finding in RBC
and not RET as owing to the much larger number of RBCs
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interrogated for the mutant phenotype (>150 million) versus
RET (approximately 3 million).
PIG-A in Human Cells
The literature search performed identified 13 studies with
PIG-A in human cells apart from those involved in studies of
paroxysmal nocturnal haemoglobinuria (PNH). The studies are
summarized in table 2 according to the year of publication.
The studies can be broadly classified (classification indicated
by letters in table 2) into studies in cancer cells (A [6,47–49]),
in cells from normal donors (B; [9,47,50–52]), in cells with
impaired DNA damage response or DNA repair defects (C
[49,50,53]), in human lymphocytes exposed to environmental
stressors (D [8]) and recently also in the TK6 cell line that is
widely used and relevant for chemical risk assessment (E
[23,24,54]).
A pioneering study involved colon cancer cell lines that
exhibited significantly higher mutation frequencies than con-
trol cell lines [6], using PIG-A mutants as a marker of mutator
phenotypes in cancer. The mutants were enriched by use of
the GPI anchor-reactive bacterial toxin that lyses cells that
express anchor proteins. In this experiment, sorted and cloned
mutants were verified by DNA sequencing.
Several of the initial studies concentrated on determining
mutation rates (mutations per cell division) rather than measur-
ing mutation frequencies (here the incidence of mutant pheno-
type cells, often expressed as number per 106 cells) [47,48,50].
It was shown that the mutation rates from donors that were
cancer prone (Fanconi anaemia (FA) and ataxia telangiectasia
(AT) were elevated compared to cell lines from normal donors
[50], as well as marked differences in mutation rates among B-
lymphoblastoid cell lines from normal donors and lymphoma
cancer patients [47] and transformed myeloid cells [48]. These
studies have given rise to important new information regarding
the rate of spontaneous mutations in human cells.
The group of Bignami et al. developed a flow cytometry-
based PIG-A gene mutation assay using three anchor mole-
cules (CD48, DC55 and CD59) to investigate the role of the
DNA repair protein MUTYH, and different spontaneous
MUTYH mutants, for mutagenesis [49,53]. They measured
PIG-A mutants in lymphoblastoid cell lines derived from
patients with MUTYH-associated colon polyposis. Pre-existing
PIG-A-mutant cells were selectively removed by flow sorting
to ascertain that the PIG-A mutation frequency measured was
due to the MUTYH defect or to KBrO3 treatment (oxidative
stress). The spontaneous PIG-A mutation frequency in the
MUTYH-mutated lymphoblastoid cell lines was 3–6 times
higher compared to wild-type levels depending on type of
MUTYH mutation and allelic presence (mono- or biallelic
mutation), suggesting that the type of MUTYH mutation con-
tributes to determine the magnitude of the mutator phenotype.
After oxidative stress (KBrO3 exposure), the PIG-A mutation
frequencies in homozygous MUTYH cell lines were more pro-
nounced than in wild-type or heterozygous cell lines.
Several approaches have been initiated to investigate normal
human donor cells. One study used the PIG-A assay, along
with a battery of other tests to assess the genotoxicity in blood
lymphocytes from Gulf War veterans exposed to depleted ura-
nium. Selected due to urine U exposure, individuals were
divided into low- and high-U groups, and results in the two
groups were compared [8]. PIG-A mutation frequencies ranged
from 2.9 to 113 9 106 (mean = 14.9 9 106). Group means
of the low-U group (18.1 9 106  4.9) were not signifi-
cantly different from the high-U group (9.5 9 106  0.8),
but interestingly the high-U group exhibited apparently lower
Mf with less variation. No clear association with age was
detected (age 43.62  5.35). Dobrovolsky et al. [51] investi-
gated 97 normal individuals (mean age 39.9  13.4; span
18–73) and 10 individuals undergoing chemotherapy (age not
stated). They found that the mean mutant RBC frequency was
5.1  4.9 9 106 and that some individuals expressed very
high mutation frequencies. They detected no clear correlation
with age and smoking status, and the patients undergoing
chemotherapy showed generally low responses. Rondelli et al.
[9] reported similar findings for granulocytes with respect to
mutation frequencies, with significant variation between indi-
viduals. To facilitate studies of human blood samples, Dertin-
ger et al. [52] recently reported on the development and initial
tests of a human blood PIG-A assay analogous to one of the
most used protocols to determine mutant RET and mutant
RBC frequencies in rodent blood samples. Expression of two
GPI-anchored proteins (CD59 and CD55) served as reporters
of PIG-A mutation, and immunomagnetic depletion of wild-
type cells was included that gives a dramatic enrichment of
mutant cells. This appears to be especially important for
human samples, as there is evidence that mutant RETs repre-
sent a better indicator of mutation compared to mutant RBCs
in humans, as there is evidence of selective pressure against
circulating human PIG-A-mutant erythrocytes due to comple-
ment-mediated lysis. The data suggested several important
characteristics of human blood-based PIG-A assays. The
mutant RET frequencies are consistently higher than the corre-
sponding mutant RBC frequencies, and this suggests that the
former may serve as a more accurate representation of muta-
tion frequency. The variation within each individual was rela-
tively low but similar to the two preceding reports in normal
human blood cells, while variability between individuals was
high. An effort has been initiated to explore factors that may
explain the large variation observed in healthy volunteers,
such as age, smoking habits. Analyses show that in the very
young (15 umbilical cord blood samples from healthy full-
term babies and five from infants), mutant RET frequencies
are consistently low, an observation that warrants confirma-
tion. With increasing age, mutant RET increased and was
accompanied with increased variation, suggesting that age is a
factor that leads to increased PIG-A mutation frequencies.
Investigation of the role of human exposure to external factors
such as environmental stressors is warranted before the assay
can be used for human biomonitoring or clinical applications.
Recently, the PIG-A assay has been successfully established
in vitro B-lymphoblastoid TK6 cells, commonly used for
in vitro mutagenicity testing, were applied [23,24,54]. The
GPI status of the cells was determined by multicolour flow
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cytometry. The GPI-linked proteins CD55 and CD59 were
stained to differentiate between mutant and wild-type cells. To
exclude unspecific events during the flow cytometric analysis,
the GPI-independent B-cell marker CD19 was stained with
allophycocyanin-conjugated antibodies to increase the sensitiv-
ity and reproducibility of the assay. Ten days of phenotype
expression time was found to be suitable after 4-hr incubations
with respective mutagens. The in vitro methodology was thor-
oughly validated by mutant spiking experiments as well as by
comparing the new flow cytometric analysis with the classical
approach based on surviving of mutant cells in a selective
media, as applied, for example, in the hypoxanthine-guanine
phosphoribosyltransferase (HPRT) or mouse lymphoma assay
[54]. To assess the sensitivity and the selectivity of the test
system, different positive and negative controls were exam-
ined. Cells were treated with known mutagens such as ethyl
methanesulphonate (EMS), NQO or ultraviolet C (UVC) irra-
diation and, after phenotype expression, mutant frequencies
were determined via flow cytometry. In all experiments,
mutant frequencies of treated samples were found to be
increased in a dose-dependent and statistically significant man-
ner when compared to untreated controls. Treatments with the
non-mutagenic compounds pyridine and cycloheximide did
not increase the mutant frequencies, which were comparable
to untreated controls in both experiments [54]. A subsequent
investigation of the genotype-to-phenotype relationship in
TK6 cells revealed that this cell line exhibits a heterozygous,
autosomal deletion of the PIG-L gene on chromosome 17
[23,24]. PIG-L is, like PIG-A, essential for the GPI biosynthe-
sis. This leads to the unique situation that inactivating muta-
tions in two genes, the X-linked PIG-A and the autosomal
PIG-L, result in a mutant, GPI-deficient phenotype in TK6
cells. It explains the comparatively high spontaneous mutation
rate in this assay, requiring the depletion of existing mutant
cells via antibody-coated cell culture dishes. However, on the
other hand, it could provide a distinct advantage: it should
enable the TK6 cell line not only to pick up point mutations,
but also clastogenic alterations, if deletions affect the PIG-L
gene on chromosome 17, as – in contrast to X-chromosomal
events – adjacent genes required for viability would still be
present on the second copy of chromosome 17. However,
more investigations are needed to verify this assumption. First
experiments in this direction revealed that the p53-proficient
TK6 cell line is more sensitive towards the mutagens EMS
and UV-C compared to the closely related, but p53-deficient
cell line WI-L2-NS, vice versa, than expected from more effi-
cient cell cycle regulation in case of p53 proficiency. Thus,
one explanation may be the fact that WI-L2-NS cells do not
carry the PIG-L deletion described for TK6 cells [24]. Future
studies will have to clarify whether the in vitro variant can
also be conducted in other cell lines, such as epithelial cells.
Usefulness in Basic Science
In addition to use in applied sciences such as chemical risk
assessment, the investigations using the Pig-a mutation assay
have proven useful also for basic research, both in vitro in cell
lines and in mouse models. Most advantage has been in
understanding roles of different DNA repair enzymes [49,53].
The role of the MutY DNA glycosylase (MUTYH), its differ-
ent mutant versions (both monoallelic and biallelic) and the
role they have as mutator phenotypes involved in colorectal
polyposis cancer have been envisioned using the PIG-A assay.
Also other proteins involved in DNA damage response and
repair have been studied by measuring PIG-A mutation fre-
quencies, such as cell lines derived from patients exhibiting
Fanconi anaemia and ataxia telangiectasia showing that the
mutation rate in these two patient groups is higher than in nor-
mal donors [50].
Mice exhibiting different deficiencies in DNA repair pro-
teins involved in protection of the genome from oxidized
DNA have been studied [34,36,37,42, Rolseth et al., unpub-
lished]. The DNA repair proteins investigated are involved
in base excision repair eliminating oxidized DNA damage
and comprise 8-oxoguanine DNA glycosylase (Ogg1), the
MutY DNA glycosylase (MutY) and three endonuclease
VIII-like DNA glycosylases (Neil1, Neil2 and Neil3) as well
as the tumour protein p53 (p53). Ogg1 and MutY work in
concert to prevent mutations from being induced after oxida-
tive stress. Oxidative stress leads to induction of the muta-
genic 8-oxoguanine (8-oxoG) that is removed by Ogg1. If
not removed, the DNA polymerases may misincorporate ade-
nine opposite 8-oxoG, which may be removed by MutY that
excises adenine from 8oxoG:A base pairs, giving a new
chance for Ogg1 to remove 8-oxoG. Studies of Ogg1-defi-
cient mice have shown no significant elevation of the spon-
taneous Pig-a mutation frequency [34,37,42], which
correlates well with the lack of cancer phenotype in this
mouse model. The Ogg1-deficient mice have been subjected
to BaP, to Se deficiency and to low dose rate gamma irradi-
ation without the Pig-a-mutant cell frequency exceeding the
wild-type levels, suggesting that the DNA damage levels
induced are being repaired via other backup DNA repair sys-
tems. In line with this, when several DNA repair enzymes
are eliminated, such as in the cancer-prone model Ogg1/
MutY/ double knockout, the Pig-a mutation frequencies
are elevated (Rolseth et al., unpublished).
Concluding Remarks
The Pig-a/PIG-A methodology detects mutations that result in
functional inactivation of the Pig-a/PIG-A gene, as opposed to
other much used genotoxicity assays such as the alkaline
comet assay that detects pre-mutagenic DNA lesions. The test
is rapid and requires only a minute volume peripheral blood,
it is easily incorporated into experiments within regulatory
toxicology, and it has been demonstrated as useful for identi-
fying and investigating genetic factors that underlie the varia-
tion in the somatic mutation rate, as well as environmental
factors that may affect it, and factors involved in cancer devel-
opment. Besides rats where the Pig-a assay has been used
more extensively, the assay is useful both in mice, with the
advantage of the variety of mouse models that exist, and in
human cells. Compared to the rat, the kinetics of mutant
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induction and persistence in mice and human beings is not
similar to the rat and seems to vary with the investigated
chemical. In ENU-treated mice, the mutant RET and RBC
appear slightly faster than in rats, and contrary to the long per-
sistence of mutants in rats, the mutants in mice slowly decline
after reaching maximum, indicating a moderate selection of
GPI-negative cells. However, based on a limited number of
studies so far, the specificity of the Pig-a assay both in mice
[31] and in human cells [23,54] appears to be good as several
known non-mutagens did not show any mutagenic effects as
opposed to (structurally related) potent mutagenic carcinogens
that showed clear mutagenic effects. Other less potent agents
such as ionizing radiation were found to cause moderate
induction of Pig-a mutants. More experiments with low-
potency agents are required to characterize in more detail the
sensitivity (the proportion of correctly identified positive stres-
sors) of the Pig-a assay in mice. Variability between individu-
als seems to be an issue both in mice and in human cells, and
needs to be taken into account during experimental design by
ensuring that the power of the study is adequate by including
sufficient numbers of individuals, or by making use of an
experimental design that takes the variability into account (re-
peated measurements in the same individual to identify tempo-
ral differences) or conduct pre-exposure assessments that
facilitate omittance of individuals with abnormal spontaneous
Mfs. The Pig-a assay is clearly a valuable complement to
other genotoxicity assays that can be included in the same
experiment, such as in vivo micronucleus assay detecting
clastogens and the in vivo comet assay in blood detecting
DNA lesions. Several studies have used a battery of genotox-
icity tests [30,32–34,37,42], including the comet assay and
mutation detection in transgenic rodents (LacZ, Big BlueTM).
On the other hand, using assays such as the haematopoietic
cell-based Pig-a assay, normal rodents can be assessed,
which may be more cost- and time-efficient, without killing
the animals. One limitation of blood-based genotoxicity
assays such as the Pig-a and the MN assays is that they
depend on the fact that the compound, or metabolite, of inter-
est is present in the bone marrow in levels reflecting those of
target tissues. In the in vivo comet assay or mutation analyses
in transgenic rodents, target tissues can be studied directly.
Positive comet assay results in the liver or a target tissue
may indicate that a negative result with Pig-a or MN may be
due to non-availability of the compound to the bone marrow.
Moreover, understanding the timing of mutation induction in
mice and human beings is vital for correct detection of a
mutagenic response.
The Pig-a assay can easily be integrated into repeat-dose
toxicology studies and has been proposed as an alternative
to transgenic rodent (TGR) mutation assays [30]. On the
other hand, the TGR mutation assay can measure mutations
in the target organ but is dependent on the fact that the
compound induces the type of mutations that the TGR sys-
tem can reveal. The combination of different genotoxicity
assays covering different modes of action of genotoxicants is
beneficial and highly recommended. A combination of Pig-a,
micronucleus and target tissue in vivo comet analyses may
serve as a good combination of genotoxicity assays, as this
combination covers a range of DNA lesions and tissue com-
partments. An important issue in chemical risk assessment is
to identify germ cell mutagens. Comparison of results from
the Pig-a assay with analyses of DNA lesions or mutations
in germ cells by the use of transgenic reporter gene mutation
assays (i.e. Big Blue) may serve useful, to understand the
predictability of Pig-a mutations in blood for germ cell
mutagenesis.
Recently, new strategies of sequencing Pig-a mutants have
emerged facilitating more feasible verification and characteri-
zation of Pig-a phenotypic mutants [25]. This is important val-
idation work that addresses the phenotype–genotype
assumptions of the assay. These advanced sequencing strate-
gies may also be useful in cases where mutational spectra data
would be beneficial, for example, when the Pig-a mutation
frequency is only marginally increased.
In human beings, PIG-A mutation analyses have obvious
potential. PIG-A is clearly suitable as a sentinel gene to study
somatic mutations and mutagens in human beings experienc-
ing real-world exposures. The initial studies performed to date
report low intraindividual differences and rather large
interindividual differences (>30-fold; [52]), which warrants
confirmation and characterization. This variation should
inform study designs; for instance, whenever possible, pre-
exposure samples should be collected. Wide interindividual
variation has other important implications, as it suggests
important lines of future research because the variation may
be a result of mutagenic factors. For example, the human
blood PIG-A assay may provide a platform to study and iden-
tify environmental, lifestyle or other host factors that influence
mutation frequency. The cross-species nature of the end-point
would be valuable in such investigations, as host or environ-
mental factors causing elevated PIG-A mutation in human
beings could be systematically studied in highly controlled
animal experiments.
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